On July 8, 2025, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital administered the ABBV-324, developed by AbbVie — to the “first patient in Asia ” as part of a global, multicenter First-in-Human Phase 1 Clinical Trial (ClinicalTrials.gov ID: NCT06858813 ).  The administration took place in Kansai Medical University Hospital. Study Details | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | ClinicalTrials.gov